Trial will take place across 50-plus sites to measure psilocybin's effect on treatment-resistant depression.
The Cleveland Clinic has launched a multisite psilocybin trial for participants with treatment-resistant depression.
Patients participating in the research will ingest either psilocybin or a placebo in capsule form. They will be randomly assigned to one of three psilocybin doses and observed for a minimum of six hours on days when they receive psilocybin under the supervision of a therapist skilled in administering psychedelic substances.
Participants will receive psilocybin at least twice, according to the Cleveland Clinic.
Researchers will follow up with the participants for 52 weeks after the initial dose.
The Clinic noted in a news release that “results so far have indicated that psilocybin may be successful in treating depression and treatment-resistant depression with psychological support.”
In 2023, the Cleveland Clinic launched its first psychedelic trial for patients with generalized anxiety disorder. Participants received a one-time dose of MindMed’s MM-120 LSD formulation.
Nearly 80% of participants in the MindMed trial reported a 50% or greater improvement in their anxiety symptoms, compared with 31% in the placebo group, according to MindMed.